The biotechnology company focuses on the research and development of drugs targeting chronic inflammatory diseases by designing immuno-modulating and anti-inflammatory molecules with a unique mechanism of action. This approach enables patients to manage immune system imbalances associated with conditions like rheumatoid arthritis and inflammatory bowel disease.
Funding
$730K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammatory diseases (CIDs) are characterized by an imbalance in the immune system, where pro-inflammatory signals outweigh pro-resolutive signals, leading to persistent inflammation and potential damage to multiple organs. Current treatments often rely on broad immunosuppression, which can result in limited efficacy and significant adverse effects, leading to treatment failure in a substantial number of cases.
Solution
IMD-Pharma is developing a new class of non-immunosuppressive anti-inflammatory drugs based on phosphorus dendrimer platforms designed to rebalance dysregulated immune systems. Their drug candidates interact with a pool of receptors highly relevant to CIDs, promoting a pro-resolutive immune response while controlling the pro-inflammatory response. This approach aims to resolve inflammation through the rehabilitation of key immune cells, such as monocytes and CD4+ T lymphocytes, with reduced adverse effects compared to traditional immunosuppressive therapies. The company's lead investigational drug, IMD-026, is in late non-clinical development for the treatment of rheumatoid arthritis.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and VEXAS syndrome, as well as the medical professionals treating these conditions.
Features
- Novel chemical modalities based on phosphorus dendrimer platforms
- Macromolecular structures with multivalent features for interaction with multiple receptors
- Demonstrated efficacy in clinically recognized animal models of rheumatoid arthritis, psoriasis, and multiple sclerosis
- Orally bioavailable drug candidates
- Specific formulations developed to increase skin penetration or access the central nervous system
- IMD-026, a lead drug candidate in late non-clinical development for rheumatoid arthritis, with potential to inhibit bone resorption and cartilage destruction